- Home
- LSAK vs AGEN Comparison
LSAK vs AGEN Comparison
Compare LSAK & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSAK
- AGEN
- Stock Information
- Founded
- LSAK 1997
- AGEN 1994
- Country
- LSAK South Africa
- AGEN United States
- Employees
- LSAK N/A
- AGEN N/A
- Industry
- LSAK Investment Bankers/Brokers/Service
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LSAK Finance
- AGEN Health Care
- Exchange
- LSAK Nasdaq
- AGEN Nasdaq
- Market Cap
- LSAK 384.3M
- AGEN 142.8M
- IPO Year
- LSAK N/A
- AGEN 2000
- Fundamental
- Price
- LSAK $4.18
- AGEN $4.55
- Analyst Decision
- LSAK
- AGEN Buy
- Analyst Count
- LSAK 0
- AGEN 2
- Target Price
- LSAK N/A
- AGEN $14.50
- AVG Volume (30 Days)
- LSAK 52.6K
- AGEN 395.5K
- Earning Date
- LSAK 09-10-2025
- AGEN 11-11-2025
- Dividend Yield
- LSAK N/A
- AGEN N/A
- EPS Growth
- LSAK N/A
- AGEN N/A
- EPS
- LSAK N/A
- AGEN N/A
- Revenue
- LSAK N/A
- AGEN $101,706,000.00
- Revenue This Year
- LSAK N/A
- AGEN $60.49
- Revenue Next Year
- LSAK N/A
- AGEN N/A
- P/E Ratio
- LSAK N/A
- AGEN N/A
- Revenue Growth
- LSAK N/A
- AGEN N/A
- 52 Week Low
- LSAK $3.39
- AGEN $1.38
- 52 Week High
- LSAK $5.60
- AGEN $7.34
- Technical
- Relative Strength Index (RSI)
- LSAK 37.78
- AGEN 48.05
- Support Level
- LSAK $4.04
- AGEN $4.36
- Resistance Level
- LSAK $4.59
- AGEN $5.20
- Average True Range (ATR)
- LSAK 0.24
- AGEN 0.27
- MACD
- LSAK -0.06
- AGEN 0.04
- Stochastic Oscillator
- LSAK 18.42
- AGEN 40.91
About LSAK Lesaka Technologies Inc.
Lesaka Technologies Inc provides payment solutions, transaction processing solutions, and financial technologies. The company operates two reportable segments: Merchant and Consumer. The company operates mainly within South Africa. The Merchant segment that derives majority revenue includes activities related to the provision of goods and services provided to corporate and other juristic entities. It earns fees from processing activities performed for its customers and revenue generated from the distribution of prepaid airtime. The Consumer segment includes activities related to the provision of financial services to customers, including bank accounts, loans, and insurance products. The firm charges monthly administration fees for all bank accounts.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).